Overview

Medivation is currently conducting a confirmatory pivotal Phase 3 clinical trial of Dimebon in patients with mild-to-moderate Alzheimer’s disease. In addition, we will continue further development of Dimebon in patients with mild-to-moderate Huntington’s disease based on the positive results seen in our Phase 2 Huntington’s disease trial. We also are conducting a clinical trial to assess MDV3100 in the treatment of castration-resistant (also known as hormone refractory) prostate cancer.

Dimebon Clinical Trials

Phase 3 Clinical Trial of Dimebon in Alzheimer’s Disease (The CONNECTION Study)

Phase 2 Study of Dimebon in Huntington’s Disease (Topline Results Announced)

MDV3100 Clinical Trials

Phase 1-2 Study of MDV3100 in Prostate Cancer

For more information about the our clinical studies, please contact Medivation at trials@medivation.com.

To learn more about clinical trials, please visit www.clinicaltrials.gov, a service of the U.S. National Institutes of Health.